Full data view for gene TSC2

The curator’s expert opinion on the classification of a variant, can be found in the
SUMMARY record. Regarding the classification, please note that where there are several
records of the same variant, the classification of that variant may differ depending on the
submitter’s conclusion.
Information The variants shown are described using the NM_000548.3 transcript reference sequence.

3 entries on 1 page. Showing entries 1 - 3.
Legend   How to query  

Effect     

Exon     

AscendingDNA change (cDNA)     

RNA change     

Protein     

P-domain     

Predict-BioInf     

Allele     

Classification method     

Clinical classification     

DNA change (genomic) (hg19)     

DNA change (hg38)     

Published as     

ISCN     

DB-ID     

Variant remarks     

Reference     

ClinVar ID     

dbSNP ID     

Origin     

Segregation     

Frequency     

Re-site     

VIP     

Methylation     

Template     

Technique     

Tissue     

Remarks     

Disease     

ID_report     

Reference     

Remarks     

Gender     

Consanguinity     

Country     

Population     

Age at death     

VIP     

Data_av     

Treatment     

Panel size     

Owner     
+/. 28 c.3200_3201delinsAA r.(?) p.(Val1067Glu) - - Unknown - pathogenic g.2129345_2129346delinsAA g.2079344_2079345delinsAA p.(V1067E) - TSC2_004235 found with TSC2 c.5069-1G>C in primary tumour and lymph node metastasis; variant not in germline DNA; validated by Sanger SEQ; also variants in ABL1, AHNAK, ATM, BCL11B, BRD3, CIC, CNBD1, ERCC2, FANCD2, FAT1, KAT6A, MNT, SH3BGR and SPEN (see paper) PubMed: Maroto 2018 - - Somatic - - BtsIMutI-, TspRI - - - DNA SEQ, SEQ-NG-I Kidney tumour, Blood Whole exome sequencing, exome capture with SureSelectXT Human All Exon V5 kit (Agilent Technologies), coverage depth 102x (primary tumour), 116x (metastasis), and 90x (blood) RCC - PubMed: Maroto 2018 patient with retroperitoneal adenopathies and metastatic lesions in femur and lungs; disease-free for >8 years following temsirolimus treatment F ? Spain - - - - Temsirolimus 1 Rosemary Ekong
+/+ 28 c.3200_3201delinsAA r.(?) p.(Val1067Glu) - - Unknown - pathogenic (dominant) g.2129345_2129346delinsAA g.2079344_2079345delinsAA - - TSC2_004235 2bp deletion of TC and 2bp insertion of AA - - - SUMMARY record - - BtsIMutI-, TspRI- - - - - - - - - - - - - - - - - - - - -
+/. 28 c.3200_3201delinsAA - p.(Val1067Glu) - - Unknown - NA g.2129345_2129346delinsAA g.2079344_2079345delinsAA p.(V1067E) - TSC2_004235 variant disrupts TSC2 function (TORC1 activity increased, similar to pathogenic TSC2); V1067E substitution decreases TSC2 stability (reduced amount of TSC2-p.V1067E); tested in 3H9 (TSC2 -/- HEK 293T) PubMed: Maroto 2018 - - In vitro (cloned) - - - - - - - - - - - - - - - - - - - - - - -
Legend   How to query  

Assessment of functional consequences - Our conclusions on the functional consequences of variants are based on the type of variant, results of in vitro functional tests (doi: 10.1002/humu.21451; doi: 10.1002/humu.22202; doi: 10.1002/humu.23963), population frequencies, output from in silico splice site prediction algorithms, and any clinical/family data available to us. We also have output from protein prediction programs in this database for comparison purposes and they are not considered in our assessment of pathogenicity. PolyPhen Predictions - Note that these results are from PolyPhen-2 and only the HumDiv classification is shown.


Screenscraping/webscraping (downloading large amounts of data using scripts) is strictly prohibited.
Use our APIs to retrieve data.